scholarly journals Tetanus Immunity Gaps in Children 5–14 Years and Men ≥ 15 Years of Age Revealed by Integrated Disease Serosurveillance in Kenya, Tanzania, and Mozambique

2016 ◽  
Vol 96 (2) ◽  
pp. 415-420 ◽  
Author(s):  
Heather M. Scobie ◽  
Minal Patel ◽  
Diana Martin ◽  
Harran Mkocha ◽  
Sammy M. Njenga ◽  
...  
Keyword(s):  
2006 ◽  
Vol 210 (S 5) ◽  
Author(s):  
AR Prusa ◽  
N Schlaff ◽  
M Hayde ◽  
P Husslein ◽  
A Pollak ◽  
...  

2005 ◽  
Vol 5 (1) ◽  
Author(s):  
Oguz Karabay ◽  
Fatma Ozkardes ◽  
Ali Tamer ◽  
Kazım Karaarslan

1989 ◽  
Vol 7 (6) ◽  
pp. 563-566 ◽  
Author(s):  
Thomas O. Stair ◽  
Michael A. Lippe ◽  
Harold Russell ◽  
John C. Feeley

2016 ◽  
Vol 23 (7) ◽  
pp. 532-534 ◽  
Author(s):  
Myron M. Levine ◽  
Marcela F. Pasetti

In this issue ofClinical and Vaccine Immunology, Scobie and colleagues (H. M. Scobie et al., Clin Vaccine Immunol 23:546–554, 2016,http://dx.doi.org/10.1128/CVI.00052-16) report a nationwide serosurvey of tetanus immunity in >2,000 Cambodian women of child-bearing age to monitor progress toward maternal and neonatal tetanus elimination. This commentary discusses vaccines as interventions for disease control, elimination, and eradication and emphasizes the importance of the tools needed to monitor the effectiveness of initiatives that deliver the vaccines programmatically.


2016 ◽  
Vol 23 (7) ◽  
pp. 546-554 ◽  
Author(s):  
Heather M. Scobie ◽  
Bunsoth Mao ◽  
Sokhal Buth ◽  
Kathleen A. Wannemuehler ◽  
Charlotte Sørensen ◽  
...  

To monitor progress toward maternal and neonatal tetanus elimination (MNTE) in Cambodia, we conducted a nationwide serosurvey of tetanus immunity in 2012. Multistage cluster sampling was used to select 2,154 women aged 15 to 39 years. Tetanus toxoid antibodies in serum samples were measured by gold-standard double-antigen enzyme-linked immunosorbent assay (DAE) and a novel multiplex bead assay (MBA). Antibody concentrations of ≥0.01 IU/ml by DAE or the equivalent for MBA were considered seroprotective. Estimated tetanus seroprotection was 88% (95% confidence interval [CI], 86 to 89%); 64% (95% CI, 61 to 67%) of women had antibody levels of ≥1.0 IU/ml. Seroprotection was significantly lower (P< 0.001) among women aged 15 to 19 years (63%) and 20 to 24 years (87%) than among those aged ≥25 years (96%), among nulliparous women than among parous women (71 versus 97%), and among those living in the western region than among those living in other regions (82 versus 89%). The MBA showed high sensitivity (99% [95% CI, 98 to 99%]) and specificity (92% [95% CI, 88 to 95%]) compared with DAE. Findings were compatible with MNTE in Cambodia (≥80% protection). Tetanus immunity gaps should be addressed through strengthened routine immunization and targeted vaccination campaigns. Incorporating tetanus testing in national serosurveys using MBAs, which can measure immunity to multiple pathogens simultaneously, may be beneficial for monitoring MNTE.


Vaccine ◽  
1993 ◽  
Vol 11 (9) ◽  
pp. 935-936 ◽  
Author(s):  
Raffaele D'Amelio ◽  
Tommaso Stroffolini ◽  
Maria Wirz ◽  
Roberto Biselli ◽  
Paolo Maria Matricardi ◽  
...  

2002 ◽  
Vol 6 (2) ◽  
pp. 87 ◽  
Author(s):  
S. Aboud ◽  
E. F. Lyamuya ◽  
E. K. Kristoffersen ◽  
R. Matre

1981 ◽  
Vol 26 (1) ◽  
pp. 24-26
Author(s):  
W. J. Morgan ◽  
Moira P. J. McGuigan ◽  
S. Williams ◽  
G. Solomon

Of 400 consecutive patients who had wounds treated in the Accident Department, 200 remembered receiving either booster injections or a full course of tetanus toxoid in the last 10 years. During this period, 182 patients received their initial toxoid injection in association with treatment of a wound in an accident department. Only 71 (38%) of these patients attended for a full course of injections. From our assessment of the wounds and the patient's anti-tetanus immunity, 79 patients (20%) were considered to be at risk of developing tetanus. By further considering the time interval elapsed between injury and treatment, a ‘high risk” group of 13 patients (3%) was recognised. It is recommended that the use of human immunoglobulin shoul I be reserved for the ‘high risk’ group, and that the remainer of the ‘at-risk’ patients should receive penecillin prophylaxis only.


2006 ◽  
Vol 210 (S 5) ◽  
Author(s):  
AR Prusa ◽  
N Schlaff ◽  
M Hayde ◽  
P Husslein ◽  
A Pollak ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document